Cellceutix Seeks FDA’s Advice on Ulcerative Proctitis Therapy

Cellceutix Seeks FDA’s Advice on Ulcerative Proctitis Therapy
cellceutixClinical stage biopharmaceutical company, Cellceutix Corporation, is submitting a request to the U.S. Food and Drug Administration (FDA) for a pre-Investigational New Drug (IND) meeting. The company, which is dedicated to developing novel treatments with oncology, dermatology and antimicrobial applications, aims to discuss the creation of a new topical defensin-mimetic compound as a therapy for ulcerative proctitis and ulcerative proctosigmoiditis. Cellceutix' compound is expected to induce remission of ulcerative proctitis and ulcerative proctosigmoiditis, which are mucosal inflammatory diseases included in the group of inflammatory bowel diseases (IBD), that affect either the rectum, in the case of proctitis, or distal colon and rectum, in the case of proctosigmoiditis. A proposal that Cellceutix plans to discuss with the FDA's Division of Gastroenterology and Inborn Errors Products, according to announced in a press release. The conditions can have variable courses, from complete resolution to easily maintained remission to frequent relapses or refractory disease, and the Chief Operating Officer at Cellceutix, James Alexander, explained that "we are continuing to explore diverse indications for which we believe our defensin-mimetic franchise can improve clinical outcomes due to the anti-in
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *